Attovia Therapeutics (ATTO) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$4.88

Estimate

-$4.61

Surprise

-5.7%

Revenue (period 2026-06-30)

$450,000

Score today

5.8/10

Revenue source: xbrl.

Attovia Therapeutics (ATTO) reported a wider loss than forecast — diluted EPS of -$4.88 against the -$4.61 estimate (a 5.7% shortfall).

• Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday — benzinga, 2026-09-04
• Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K — benzinga, 2026-09-02
• Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30 — benzinga, 2026-08-31

TrendMatrix currently rates ATTO Sell at 5.8/10; no pre/post engine snapshot brackets this report.

0 of the last 1 quarters beat the estimate; this quarter's -5.7% surprise compares with a -5.7% four-quarter average. Next scheduled report: 2026-11-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$23.82

Price target

$36.71

Stop

$22.15

Upside to target

+54.1%

Reward-to-risk

3.6:1

Model outputs from TrendMatrix’s engine as of 2026-09-09 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.08B

P/E (fwd)

-9.9

52-week range

$16.15–$28.00

Off 52-week high

14.9%

RSI (14)

56

Volume vs avg

0.39×

Score today

5.8/10